Functional crosstalk of the glycine transporter GlyT1 and NMDA receptors

被引:17
|
作者
Piniella, Dolores [1 ,2 ]
Zafra, Francisco [1 ,2 ,3 ]
机构
[1] Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cient, Madrid, Spain
[2] Inst Hlth Carlos III ISCIII, IdiPAZ, Madrid, Spain
[3] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, C Nicolas Cabrera 1, Madrid 28049, Spain
关键词
Glutamate; Glycine; NMDA receptors; Glycine transporters; Synapse; N-METHYLGLYCINE SARCOSINE; TARGETED POINT MUTATIONS; D-ASPARTATE RECEPTORS; SELECTIVE INHIBITOR; NEGATIVE SYMPTOMS; SUBUNIT ARRANGEMENT; D-SERINE; IN-VIVO; PHARMACOLOGICAL CHARACTERIZATION; CONFORMATIONAL DYNAMICS;
D O I
10.1016/j.neuropharm.2023.109514
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
NMDA-type glutamate receptors (NMDARs) constitute one of the main glutamate (Glu) targets in the central nervous system and are involved in synaptic plasticity, which is the molecular substrate of learning and memory. Hypofunction of NMDARs has been associated with schizophrenia, while overstimulation causes neuronal death in neurodegenerative diseases or in stroke. The function of NMDARs requires coincidental binding of Glu along with other cellular signals such as neuronal depolarization, and the presence of other endogenous ligands that modulate their activity by allosterism. Among these allosteric modulators are zinc, protons and Gly, which is an obligatory co-agonist. These characteristics differentiate NMDARs from other receptors, and their structural bases have begun to be established in recent years. In this review we focus on the crosstalk between Glu and glycine (Gly), whose concentration in the NMDAR microenvironment is maintained by various Gly transporters that remove or release it into the medium in a regulated manner. The GlyT1 transporter is particularly involved in this task, and has become a target of great interest for the treatment of schizophrenia since its inhibition leads to an increase in synaptic Gly levels that enhances the activity of NMDARs. However, the only drug that has completed phase III clinical trials did not yield the expected results. Notwithstanding, there are additional drugs that continue to be investigated, and it is hoped that knowledge gained from the recently published 3D structure of GlyT1 may allow the rational design of more effective new drugs. This article is part of the Special Issue on "The receptor-receptor interaction as a new target for therapy".
引用
收藏
页数:16
相关论文
共 50 条
  • [22] THE ROLE OF N-GLYCOSYLATION IN THE TARGETING AND ACTIVITY OF THE GLYT1 GLYCINE TRANSPORTER
    OLIVARES, L
    ARAGON, C
    GIMENEZ, C
    ZAFRA, F
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (16) : 9437 - 9442
  • [23] The glycine transporter GLYT1 functions as an organic osmolyte transporter in early preimplantation embryos.
    Steeves, CL
    Hammer, MA
    Walker, G
    Rae, D
    Baltz, JM
    BIOLOGY OF REPRODUCTION, 2003, 68 : 343 - 343
  • [24] Glycine transporter 1 (GlyT1) is a novel therapeutic target for Alzheimer's disease
    Yoo, Miran
    Kim, Seong Muk
    Lee, Juho
    Kim, Hye-Ju
    Park, Seong Jeong
    ALZHEIMERS & DEMENTIA, 2024, 20 (06) : 4381 - 4381
  • [25] Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors
    Lindsley, Craig W.
    Wolkenberg, Scott E.
    Kinney, Gene G.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (17) : 1883 - 1896
  • [26] MEDI 220-Glycine transporter 1 (GlyT1) inhibitors for the treatment of schizophrenia
    Wolkenberg, Scott E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 236
  • [27] Mechanisms of endoplasmic-reticulum export of glycine transporter-1 (GLYT1)
    Fernandez-Sanchez, Enrique
    Diez-Guerra, F. Javier
    Cubelos, Beatriz
    Gimenez, Cecilio
    Zafra, Francisco
    BIOCHEMICAL JOURNAL, 2008, 409 (03) : 669 - 681
  • [28] The Glycine Transporter 1 Gene (GLYT1) Is Associated With Methamphetamine-Use Disorder
    Morita, Yukitaka
    Ujike, Hiroshi
    Tanaka, Yuji
    Kishimoto, Makiko
    Okahisa, Yuko
    Kotaka, Tatsuya
    Harano, Mutsuo
    Inada, Toshiya
    Komiyama, Tokutaro
    Hori, Toru
    Yamada, Mitsuhiko
    Sekine, Yoshimoto
    Iwata, Nakao
    Iyo, Masaomi
    Sora, Ichiro
    Ozaki, Norio
    Kuroda, Shigetoshi
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2008, 147B (01) : 54 - 58
  • [29] Glycine release from astrocytes via functional reversal of GlyT1
    Shibasaki, Koji
    Hosoi, Nobutake
    Kaneko, Ryosuke
    Tominaga, Makoto
    Yamada, Katsuya
    JOURNAL OF NEUROCHEMISTRY, 2017, 140 (03) : 395 - 403
  • [30] Progress towards validation of the NMDA hypofunction hypothesis of schizophrenia: Discovery and development of centrally active glycine transporter (GlyT1) inhibitors
    Lindsley, Craig W.
    Hartman, George D.
    Williams, David L.
    Sur, Cyrille
    O'Brien, Julie
    Lemaire, Wei
    Chang, Raymond S.
    Kinney, Gene G.
    Pettibone, Douglas J.
    Duggan, Mark E.
    Zhao, Zhijian
    Burno, Maryann
    Conn, P. J.
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S25 - S25